Clinical Trials Directory

Trials / Completed

CompletedNCT01459965

Stenting Malignant Jaundice for Quality of Life

Endoscopic Palliation of Malignant Biliary Tract Obstruction: Emphasis on Improvement in Quality of Life

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
164 (actual)
Sponsor
Indiana University · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Endoscopic stent insertion is considered the method of choice for palliation of malignant bile duct obstruction (MBDO). However, it can cause complications and requires periodic stent exchanges. While endoscopic stenting is clearly indicated for relief of cholangitis or refractory pruritus, its role in patients with jaundice alone is less clear. Endoscopic stenting for this relative indication might be justified, if there is a significant improvement in quality of life (QOL) of such patients. The aim of the investigators study was to determine whether endoscopic stenting for MBDO results in improved QOL.

Detailed description

Most malignant tumors causing bile duct obstruction, such as pancreatic adenocarcinoma, gallbladder carcinoma or cholangiocarcinoma, have an extremely poor prognosis. At the time of diagnosis the majority of these tumors will be unresectable with a median survival of 4-6 months. Palliation is the goal for those patients with unresectable tumors and limited survival and for those at high risk for attempts at curative resection. Endoscopic retrograde cholangiopancreatography (ERCP) with endoscopic stent insertion is considered the method of choice for palliative treatment of malignant bile duct obstruction (MBDO). However, it can cause complications, such as pancreatitis, bleeding, perforation, cholangitis and stent migration in a significant proportion of treated patients. Clogging of plastic stents is a predictable consequence and requires periodic stent exchanges with attendant risks and costs. While endoscopic stenting is clearly indicated for relief of cholangitis or refractory pruritus, the role of stenting in patients with jaundice alone, abdominal pain, or failure to thrive due to malignancy is less clear. Given the risk for complications and costs, endoscopic therapy might be justified in these clinical scenarios if quality of life (QOL) is significantly improved. A few available studies have demonstrated improved QOL in stented patients. However, these studies include a small number of patients and/or are retrospective in design. Therefore, more evidence to support routine palliative biliary drainage in patients with MBDO is desired.

Conditions

Interventions

TypeNameDescription
PROCEDUREERCP with 10 French biliary plastic stent placementStent placement of a 10 French biliary plastic stent
PROCEDUREERCP with 11.5 French biliary plastic stentbiliary plastic stent placement

Timeline

Start date
1993-07-01
Primary completion
2004-11-01
Completion
2004-11-01
First posted
2011-10-26
Last updated
2011-10-26

Source: ClinicalTrials.gov record NCT01459965. Inclusion in this directory is not an endorsement.